Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical PET Imaging Evaluation of 68Ga-NB381 Probe in Multiple Myeloma
NCT06385652Phase 1Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NB381 in multiple myeloma (MM), sponsored by Peking University First Hospital. Primary endpoints: Specificity and Binding Efficiency of 68Ga-NB381 in CD38 Positive Tumors at 1 week and Baseline Pathological Characteristics: Histopathology, Flow Cytometry, and Immunohistochemistry. Started Apr 2024; status: recruiting.
02
Drugs
68Ga-NB381
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06385652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385652.